

# A Systematic Review of Chronic Fatigue Syndrome: Don't Assume It's Depression

James P. Griffith, M.D., F.A.C.P., and Fahd A. Zarrouf, M.D.

---

**Objective:** Chronic fatigue syndrome (CFS) is characterized by profound, debilitating fatigue and a combination of several other symptoms resulting in substantial reduction in occupational, personal, social, and educational status. CFS is often misdiagnosed as depression. The objective of this study was to evaluate and discuss different etiologies, approaches, and management strategies of CFS and to present ways to differentiate it from the fatigue symptom of depression.

**Data Sources:** A MEDLINE search was conducted to identify existing information about CFS and depression using the headings *chronic fatigue syndrome AND depression*. The alternative terms *major depressive disorder* and *mood disorder* were also searched in conjunction with the term *chronic fatigue syndrome*. Additionally, MEDLINE was searched using the term *chronic fatigue*. All searches were limited to articles published within the last 10 years, in English. A total of 302 articles were identified by these searches. Also, the term *chronic fatigue syndrome* was searched by itself. This search was limited to articles published within the last 5 years, in English, and resulted in an additional 460 articles. Additional publications were identified by manually searching the reference lists of the articles from both searches.

**Study Selection and Data Extraction:** CFS definitions, etiologies, differential diagnoses (especially depression) and management strategies were extracted, reviewed, and summarized to meet the objectives of this article.

**Data Synthesis:** CFS is underdiagnosed in more than 80% of the people who have it; at the same time, it is often misdiagnosed as depression. Genetic, immunologic, infectious, metabolic, and neurologic etiologies were suggested to explain CFS. A biopsychosocial model was suggested for evaluating, managing, and differentiating CFS from depression.

**Conclusions:** Evaluating and managing chronic fatigue is a challenging situation for physicians, as it is a challenging and difficult condition for patients. A biopsychosocial approach in the evaluation and management is recommended. More studies about CFS manifestations, evaluation, and management are needed.

(*Prim Care Companion J Clin Psychiatry* 2008;10:120-128)

---

Received July 20, 2007; accepted Sept. 14, 2007. From the Internal Medicine/Psychiatry Residency Program, West Virginia University, Charleston.

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Corresponding author and reprints: Fahd A. Zarrouf, M.D., Medicine/Psychiatry Residency Program, West Virginia University, 501 Morris St., 4 West, Charleston, WV 25326 (e-mail: fahdzarrouf@hotmail.com).

*"She is depressed," her physician wrote when referring Ms. A, a 65-year-old married woman, for a psychiatric consult. "She has been feeling tired for more than a year and described being exhausted most of the time, with headaches, joint pain, and problems with her concentration and memory. Her fatigue is frustrating for her and for her family; she cannot function well even in the morning. She denied being depressed, and does not have any previous mental or medical illnesses. Every lab I checked was normal. I still think that she is hiding her depression and manifesting it with all these somatic complaints."*

Prolonged fatigue is defined as self-reported, persistent fatigue of 1 month or longer.<sup>1</sup> Chronic fatigue syndrome (previously known as myalgic encephalomyelitis<sup>2</sup> or neurasthenia<sup>3</sup>) is characterized by profound, debilitating fatigue and a combination of symptoms resulting in substantial reduction in occupational, personal, social, and educational status<sup>1,2,4-7</sup> (see Table 1). Diagnosis of the chronic fatigue syndrome (CFS) can be made only after alternate medical and psychiatric causes of chronic fatiguing illness have been excluded.

At least 1 million Americans have CFS,<sup>1,8</sup> more than have lung cancer or multiple sclerosis; yet more than 80% go undiagnosed. In the primary care setting, the prevalence of CFS ranges from 3% to 20% and from 80% to 90% at the end of life.<sup>9,10</sup> There are no ethnic or racial differences. Previous reports have mentioned a female:male ratio of 1.3:1,<sup>6</sup> but a recent report by the U.S. Centers for Disease Control and Prevention (CDC) showed a female:male ratio of 4:1. It occurs most often in the 40- to 59-year age group and in the geriatric population.<sup>1,9,10</sup>

Although the concept of neurasthenia was introduced in 1869 by George Miller Beard,<sup>3</sup> CFS was defined in 1988 by the CDC, and while more than 3000 research studies have been done in this field, there is still some debate about the existence of this syndrome.<sup>1,11,12</sup> The

**Table 1. Chronic Fatigue Syndrome Criteria<sup>a</sup>**

1. Unexplained, persistent fatigue that is not due to ongoing exertion, is not substantially relieved by rest, is of new onset (not lifelong), and results in a significant reduction in previous levels of activity
- AND
2. Four or more of the following symptoms are present for 6 months or more:
    - Impaired memory or concentration
    - Postexertional malaise (extreme, prolonged exhaustion and exacerbation of symptoms following physical or mental exertion)
    - Unrefreshing sleep
    - Muscle pain
    - Multijoint pain without swelling or redness
    - Headaches of a new type or severity
    - Sore throat that's frequent or recurring
    - Tender cervical or axillary lymph nodes

<sup>a</sup>From the Centers for Disease Control and Prevention.<sup>1</sup>

uncertainty about its existence and the lack of a specific laboratory test or marker to identify it, associated with hesitancy about making a diagnosis without knowing exactly how to treat it, all act as barriers to the diagnosis and treatment of CFS by primary care practitioners and psychiatrists.

Unlike the uncertainty about its existence, there is strong certainty about the impact of CFS. CFS patients, by definition, are functionally impaired and as disabled as patients with multiple sclerosis, heart disease, end-stage renal disease, and similar chronic conditions. The annual economic impact of CFS in the United States is estimated to be \$9.1 billion in lost productivity.<sup>1</sup>

### DATA SOURCES

A MEDLINE search was conducted to identify existing information about CFS and depression using the headings *chronic fatigue syndrome* AND *depression*. The alternative terms *major depressive disorder* and *mood disorder* were also searched in conjunction with the term *chronic fatigue syndrome*. Additionally, MEDLINE was searched using the term *chronic fatigue*. All searches were limited to articles published within the last 10 years, in English. A total of 302 articles were identified by these searches. Also, the term *chronic fatigue syndrome* was searched by itself. This search was limited to articles published within the last 5 years, in English, and resulted in an additional 460 articles. Additional publications were identified by manually searching the reference lists of the articles from both searches.

### FATIGUE ETIOLOGIES

CFS cannot be considered either physical or psychological but instead requires a biopsychosocial approach to the illness. Numerous studies have tried to pinpoint specific etiologies by considering the following fields.

### Genetic Etiologies

CFS is sometimes seen in members of the same family,<sup>13,14</sup> but there is no evidence that it is contagious; instead, there may be a familial predisposition or a genetic link. The concordance rate was higher in monozygotic than in dizygotic female twins for chronic fatigue.<sup>15</sup> Hickie et al.<sup>16</sup> evaluated genetic and environmental determinants of prolonged fatigue in a twin study and found 44% (95% CI = 25% to 60%) of the genetic variance for fatigue was not shared by the other forms of psychological distress, and also found that environmental factors made negligible contributions to fatigue. On the other hand, Cho et al.<sup>17</sup> found evidence of a partly genetic influence, but environmental effects continued to be predominant. Clearly, further research is needed to explore these possible relationships.

### Immunologic Etiologies

Abnormal natural killer cell cytotoxicity,<sup>18</sup> increase immune activation markers,<sup>19</sup> greater numbers of CD16<sup>+</sup>/CD3<sup>-</sup> natural killer cells,<sup>20</sup> and the presence of interferon in serum and cerebrospinal fluid in CFS patients<sup>21</sup> have been identified. Staines<sup>22</sup> suggested the loss of immunologic tolerance to vasoactive neuropeptides or their receptors following infection, other events, or de novo as a mechanism.

### Infectious Etiologies

Possible infectious etiologies have generated the most interest among CFS researchers. It has been postulated that chronic fatigue is a continuum ranging from cases with chronic viremia on the one hand to instances of frank psychiatric illness on the other.<sup>23</sup> Multiple infectious agents have been linked to CFS, including Borna disease virus,<sup>24,25</sup> parvovirus B19,<sup>26,27</sup> glandular fever,<sup>28</sup> Enterovirus,<sup>29</sup> human herpesviruses 4, 6, and 7,<sup>30-32</sup> infectious mononucleosis,<sup>33</sup> Nipah virus encephalitis,<sup>34</sup> and Q fever.<sup>35</sup>

Infections have not only played important etiologic roles, but also have been considered predictors of better prognoses when compared to noninfectious CFS cases.<sup>36</sup> Human herpesvirus 6 reactivation has been suggested as an objective biomarker for fatigue.<sup>30</sup>

### Endocrinology/Metabolism Etiologies

Hypothalamic-pituitary-adrenal (HPA) axis abnormalities have been studied as potential biological tests to diagnose CFS. Studies have shown HPA hypoactivity and higher chronic adrenocorticotropic hormone (ACTH) autoantibody levels as significant pathologic factors in CFS.<sup>37-39</sup> Also reduced area under the ACTH response curve in CFS patients undergoing insulin tolerance test was significantly associated with the duration of CFS symptoms ( $r = -0.592$ ,  $p = .005$ ) and the severity of fatigue symptomatology.<sup>40</sup> Other studies have suggested

upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome but not in those with primary depression.<sup>41</sup> However, another study showed no etiologic role for deficiency in central opioids or the HPA axis in the symptoms of CFS.<sup>42</sup> Other biological factors have been investigated and considered as biological markers in CFS, including low magnesium level,<sup>43</sup> low arachidonic acid level, low L-carnitine level,<sup>25</sup> serum dehydroepiandrosterone (DHEA) sulfate deficiency,<sup>44</sup> and impairments of the 2',5'-oligoadenylate (2-5A) synthetase/RNase L pathway.<sup>45</sup> Other studies showed no role of linoleic acid, eicosatrienoic acid (both  $p > .05$ ),<sup>25</sup> ferritin, vitamin B<sub>12</sub>, folate, or serum erythropoietin levels.<sup>46</sup>

### Mental/Neurologic Etiologies

Psychosocial factors are frequently thought to contribute to fatigue. Rangel et al.<sup>13</sup> found that CFS in childhood and adolescence is associated with higher levels of parental mental distress, emotional involvement, and family illness burden than those observed in association with juvenile rheumatoid arthritis, a chronic pediatric physical illness. Endicott<sup>14</sup> described stressors including earlier mortality age and increased prevalence of cancer, autoimmune disorders, and CFS-like conditions in parents of psychiatric patients with CFS as compared to control groups. Thirty percent of the CFS patients and none of the controls reported dilemmas in the 3 months prior to the CFS onset in one study.<sup>47</sup> History of abuse, particularly during childhood, may play a role in the development and perpetuation of chronic fatigue,<sup>48</sup> and childhood trauma was associated with a 3- to 8-fold increased risk for CFS across different trauma types in one study.<sup>49</sup> Sleep is also an interesting etiologic factor, as many patients with CFS have sleep disorders, and those with sleep disorders showed greater functional impairment independent of their psychiatric disorders.<sup>50-52</sup>

### FATIGUE: DON'T ASSUME IT'S DEPRESSION

Fatigue is a part of a wide spectrum of diagnoses ranging from being a symptom in depression, anxiety, seasonal affective disorder,<sup>53</sup> and multiple other diagnoses to being a full syndromal disorder in CFS, yet CFS goes undiagnosed in 80% of cases and is often misdiagnosed as depression. The *Diagnostic and Statistical Manual of Mental Disorders* doesn't list CFS as a diagnosis although the *International Classification of Diseases, 10th Revision*, does.<sup>12</sup> In clinical practice, CFS presentations range from complicated cases associated with a psychotic state resulting in multiple murders in one case report<sup>54</sup> to noncomplicated presentations with multiple psychiatric disorders, primarily depression.<sup>55</sup> It is very important to understand the distinctive features between chronic fatigue and depressive disorder when evaluating a patient

with a main complaint of fatigue. A full detailed history accompanied by questionnaire forms can be very helpful to differentiate CFS from major depressive disorder. There is still no specific test that can confidently differentiate between them. Multiple studies have tried to find distinctive factors and they are listed in Table 2.

### EVALUATION OF FATIGUE

Diagnosing CFS can be challenging for health care professionals for many reasons; the most important one is finding fatigue in a large number of illnesses and disorders. We reviewed information available about evaluation of chronic fatigue and discuss it in 3 parts: history, exam, and diagnostic tests.

#### History and Differentials

Because CFS is a diagnosis of exclusion,<sup>1</sup> a full detailed history is considered essential. The history should include a detailed account of the symptoms, the associated disability, the choice of coping strategies, and importantly, the patient's own understanding of his/her illness.<sup>65</sup> Every patient should be carefully evaluated for certain medical, psychiatric, and neurologic diseases that can cause fatigue as the most prominent symptom (Table 3). Two of the important differential diagnoses are depression and fibromyalgia. Although it is difficult to differentiate CFS from fibromyalgia confidently depending on the history or other reported differences of cognitive dysfunction components or clinical pain measures,<sup>66,67</sup> CFS and fibromyalgia commonly co-occur within the concept of central sensitivity syndromes or functional somatic syndromes.<sup>68</sup> This co-occurring increases functional impairment when compared to CFS individuals alone.<sup>69,70</sup> Some of the distinguishing features between CFS and fibromyalgia include evidence for triggering viral infection and lower level of serum acylcarnitine observed in CFS patients, which is lacking in the majority of patients with fibromyalgia;<sup>71</sup> slower information-processing in CFS patients compared to impaired control of attention in fibromyalgia patients;<sup>66</sup> and lacking of the characteristic diffuse soft tissue pain and pain on palpation in at least 11 of 18 paired tender points in CFS patients.

#### Exam

Every CFS evaluation should include a mental status examination to identify abnormalities in mood, intellectual function, memory, and personality. Particular attention should be directed toward current symptoms of depressive, anxious, self-destructive thoughts and observable signs such as psychomotor retardation.<sup>1</sup> Although there is no definite physical finding, a full and thorough physical examination may be helpful in excluding other conditions. Multiple studies have suggested dysautonomia with greater increase in heart rate together

**Table 2. Comparison Between Chronic Fatigue Syndrome (CFS) and Depression Across Different Studies**

Domain	CFS	Depression
History	Postexertional malaise <sup>56</sup> Unrefreshing sleep/excessive sleep <sup>56</sup> Fatigue is associated with intense frustration at not functioning well <sup>57</sup> Patients are less likely to interpret symptoms in terms of negative emotional states <sup>58</sup> Patients attribute their illness to external or somatic experiences <sup>59,60</sup> More likely to cope with their illness by limiting stress and activity levels <sup>59</sup> Difficulties in the doctor-patient relationship related to frustration of no diagnosis <sup>61</sup>	Feeling better after exercise/activities Insomnia or excessive sleep Fatigue is associated with apathy and anhedonia Patients are more likely to interpret symptoms in terms of negative emotional states Patients may attribute their illness to psychological factors More likely to cope with their illness by increasing their activity levels Less likely to develop difficulties in the doctor-patient relationship, and most likely related to treatment or comorbid disorders
Physical and mental status examinations	Patients are weaker and they have more pain complaints <sup>62</sup> Sore throat that is frequent or recurring <sup>1</sup> Tender cervical or axillary lymph nodes <sup>1</sup> CFS patients generally performed worse on cognitive tests than healthy controls, but better than patients with MDD <sup>63</sup>	Patients are stronger and they have fewer pain complaints NA NA MDD patients generally performed worse on cognitive tests than healthy controls, and worse than patients with CFS
Diagnostic tests <sup>a</sup>	Low DHEA level <sup>64</sup> Sleep studies showed more non-REM sleep disturbances <sup>56</sup> More resting T (CD3 <sup>+</sup> /CD25 <sup>-</sup> ) cells. Fewer CD20 <sup>+</sup> /CD5 <sup>+</sup> B cells <sup>20</sup>	Low DHEA sulfate derivative level Sleep studies showed more REM sleep disturbances Fewer resting T (CD3 <sup>+</sup> /CD25 <sup>-</sup> ) cells. More CD20 <sup>+</sup> /CD5 <sup>+</sup> B cells

<sup>a</sup>There is no definite diagnostic test.

Abbreviations: DHEA = dehydroepiandrosterone, MDD = major depressive disorder, NA = not applicable, REM = rapid eye movement.

with a more pronounced systolic blood pressure fall on standing in CFS patients compared to healthy individuals.<sup>46,72</sup> Other studies found no statistically significant differences in either heart rate or galvanic skin resistance both during a normal day and before, during, and after exercise testing.<sup>73</sup>

### Tests

The CDC has recommended the following initial screening tests when evaluating patients with CFS: urinalysis, total protein, glucose, C-reactive protein, phosphorus, electrolyte, complete blood count with leukocyte differential, alkaline phosphatase, creatinine, blood urea nitrogen, albumin, antinuclear antibody and rheumatoid factor, globulin, calcium, alanine aminotransferase or aspartate transaminase serum level, and thyroid function tests (thyroid stimulating hormone and free T4).<sup>1</sup> Further tests or referral to specialists may be indicated to confirm or exclude a diagnosis that better explains the fatigue state or to follow up on results of the initial screening tests.

Multiple other studies have tried to find biomarkers or radiological markers for CFS. Erythrocyte sedimentation rate was normal in all 23 CFS patients in one study.<sup>74</sup> Another study found that concentrations of C-reactive protein,  $\beta_2$ -microglobulin, and neopterin were higher in patients with CFS ( $p \leq .01$ ).<sup>75</sup> On the other hand, a study by Swanink et al.<sup>76</sup> found that complete blood cell count,

serum chemistry panel, C-reactive protein, and serologic tests were not different in 88 patients with CFS when compared to a control group. A potential role for DHEA in CFS, both therapeutically and as a diagnostic tool, was suggested in one study.<sup>64</sup>

Magnetic resonance imaging studies have been inconsistent, with some of them suggesting larger ventricular volumes.<sup>77-84</sup> Functional magnetic resonance was more promising, as it showed quantitative and qualitative differences in activation of the working memory network,<sup>85</sup> attenuation of the responsiveness to stimuli not directly related to the fatigue-inducing tasks,<sup>86</sup> utilization of more extensive regions of the network associated with the verbal working memory system,<sup>87</sup> impaired functioning and reduced gray-matter volume in the bilateral prefrontal cortex,<sup>88</sup> and inactive ventral anterior cingulate after making an error.<sup>89</sup>

Single-photon emission computed tomography (SPECT) and brain electrical activity mapping scans were promising in one study,<sup>90</sup> and SPECT scans showed more abnormalities than did magnetic resonance scans in one study ( $p < .025$ ).<sup>91</sup> Siessmeier et al.<sup>92</sup> detected abnormalities in 18-fluorodeoxyglucose positron emission tomography in approximately half the CFS patients examined, but found that no specific pattern for CFS could be identified. Positron emission tomography showed an alteration of the serotonergic system in the rostral anterior cingulate

**Table 3. Chronic Fatigue Syndrome Differential Diagnoses**

Psychiatric/neurological disorders
Depressive disorders
Anxiety disorders
Fibromyalgia
Substance abuse/dependence
Sleep disorders
Infectious diseases
Herpesvirus infections
Lyme disease
Parvovirus B19
Borna disease virus
Glandular fever
Human mononucleosis
Q fever
Enterovirus
Nipah virus encephalitis
Endocrine diseases
Hypothyroidism
Severe obesity
Diabetes mellitus
Immunologic disorders
Lupus
Multiple sclerosis
Temporomandibular joint disorder
Others
Medications
Irritable bowel syndrome
Multiple chemical sensitivity
Gulf War syndrome
Interstitial cystitis

in one study, which was suggested as an etiology.<sup>93</sup> Recently, Puri<sup>94</sup> described the application of proton neurospectroscopy and 31-phosphorus neurospectroscopy in chronic fatigue syndrome. It is essential to mention that evidence to date does not support routine use of the imaging modalities discussed above in evaluating potential CFS patients.

Finally, it is important to remember that a good history is more important than any available test to diagnose CFS and differentiate it from depression. The algorithm shown in Figure 1, which is based on the CDC recommendations and the results of the studies reviewed, is suggested for evaluating chronic fatigue.

### MANAGEMENT OF FATIGUE

It is important to manage fatigue in the context of each patient suffering with it. Treatment of CFS, with its various major clinical and functional impacts, should be associated with a “biopsychosocial model” of management. Educating patients about their diagnoses is crucial. Physicians should emphasize distinction among factors that may have predisposed patients to develop, trigger, or perpetuate the illness.<sup>65</sup> Progressive muscular rehabilitation, combined with behavioral and cognitive treatment, and appropriate choice of medications are essential parts of therapy.<sup>8</sup>

We will review the major concepts of CFS management and the evidence behind them.

### Supportive and Symptomatic Treatment

Educating patients about CFS and validating their illness experience in addition to establishing a working alliance are the initial steps in the treatment.<sup>1,65</sup> Direct the treatment toward the most problematic symptoms, as prioritized by the patient,<sup>1</sup> and other illness-perpetuating factors.<sup>65</sup> Encourage a well-balanced diet, and discuss with patients their nutritional habits. Advice about preventing over- and under-activity is essential. “Start low and go slow” is the correct advice for activities and exercise, the same as for using medications. Gear activities toward improving function in areas that are of greatest importance in achieving activities of daily living and remain open-minded about alternative therapies (electroacupuncture was helpful in one study<sup>95</sup>) and discuss them with your patients when appropriate.<sup>1</sup> Consider referring or asking for consults and discuss that with patients early in the treatment.

### Cognitive Behavioral Therapy

The short-term studies of cognitive behavioral therapy (CBT) in CFS have shown improvement in function and symptom management, especially in conjunction with other treatment modalities and in comparison to relaxation controls.<sup>96–99</sup> Reports about good outcome following CBT ranged from 70%<sup>99</sup> to none or even worsening of the symptoms.<sup>100</sup> CBT was effective in treating symptoms of fatigue, mood, and physical fitness, but no improvement in cognitive function or quality of life was noticed in one study.<sup>101</sup> Other studies showed limited effect on pain and fatigue.<sup>1</sup> When treating CFS patients, the CBT therapist needs to be familiar with CFS, to be aware of the evidence for CFS as a biologically based disorder, and to validate the patient’s experience of living with a misunderstood illness.


### Exercise

CFS patients are very sensitive, and any treatment modality including exercise should start low and advance slowly. All exercises need to be followed by a rest period at a 1:3 ratio (i.e., 10 minutes of exercise: 30 minutes of rest). Review of the studies showed that exercise decreased the psychological stress<sup>102</sup> and improved fatigue, functional capacity, and fitness significantly better than flexibility treatment,<sup>103</sup> especially when associated with mood-enhancing, stress-reducing activities.<sup>104,105</sup>

### Pharmacologic Treatment

Multiple studies have evaluated different treatment interventions, including recombinant erythropoietin, psychostimulants, corticosteroids, anti-inflammatory drugs, L-carnitine, and others.<sup>10,106</sup> Antidepressants are the most common medications used in this regard; selegiline had a small but significant therapeutic effect independent of its antidepressant effect.<sup>107</sup> Fluoxetine has been shown to

Figure 1. Algorithm for Evaluating Chronic Fatigue Syndrome (CFS)



<sup>a</sup>Adapted from the Centers for Disease Control and Prevention.<sup>1</sup>  
Abbreviation: CDC = Centers for Disease Control and Prevention.

improve overall symptoms and measures of immune function in one study,<sup>108</sup> but failed in randomized, double-blind studies against placebo<sup>109</sup> and graded exercise.<sup>110</sup> Bupropion was effective for treatment of the fatigue and depressive symptoms associated with CFS in 9 fluoxetine-resistant patients<sup>111</sup> and was also helpful in augmenting paroxetine in one case report.<sup>112</sup> Venlafaxine was effective in 2 case reports.<sup>113</sup> Moclobemide up to 600 mg a day for 6 weeks showed significant but small reductions in fatigue, depression, anxiety, and somatic amplification, as well as a modest overall improvement.<sup>114</sup> Duloxetine may have a theoretical therapeutic benefit because of its characteristic of targeting pain. We could not find any study evaluating it in CFS patients. It is essential to mention that evidence to date does not support superiority of one medication over the others.

Other medications have been studied also. Clonidine enhanced both growth hormone ( $p = .028$ ) and cortisol release ( $p = .021$ ) and increased speed in the initial stage of a planning task ( $p = .023$ ) only without affecting hormonal, physiologic, symptomatic, or neuropsychological measures.<sup>115</sup> Low-dose hydrocortisone therapy caused increases in plasma leptin levels, with this biological response being more marked in those CFS subjects who showed a positive therapeutic response to hydrocortisone therapy.<sup>116</sup> Essential fatty acid supplement rich in eicosapentaenoic acid was beneficial in a case report.<sup>117</sup> Carnitine supplementation has been shown to reduce chronic inflammation and oxidative stress in hemodialysis patients and, in cancer patients, reduce fatigue and improve outcome.<sup>118</sup> Treatment with modafinil was not beneficial in patients with CFS in one study.<sup>119</sup>

No therapeutic effects were found for natural killer cell stimulant,<sup>120</sup> low-dose combination therapy of hydrocortisone and fludrocortisone,<sup>121</sup> immunologic and antiviral substances, melatonin, or bright-light phototherapy.<sup>122</sup>

## CONCLUSION

Evaluating and managing chronic fatigue is a challenging situation for physicians as it is a challenging and difficult condition for patients. A biopsychosocial approach in the evaluation and management is recommended. More studies about CFS manifestations, evaluation, and management are needed.

**Drug names:** bupropion (Wellbutrin and others), duloxetine (Cymbalta), clonidine (Catapres, Duraclon, and others), fluoxetine (Prozac and others), hydrocortisone (Cortef, Texacort, and others), modafinil (Provigil), paroxetine (Paxil, Pexeva, and others), selegiline (Eldepryl, Emsam, and others), venlafaxine (Effexor).

## REFERENCES

- Centers for Disease Control and Prevention. Chronic Fatigue Syndrome. May 26, 2006. Available at: [www.cdc.gov/cfs](http://www.cdc.gov/cfs). Accessed Feb 3, 2007
- Wessely S. The epidemiology of chronic fatigue syndrome. *Epidemiol Rev* 1995;17:139–151
- Schafer ML. On the history of the concept neurasthenia and its modern variants chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities [in German]. *Fortschr Neurol Psychiatr* 2002;70(11):570–582
- Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. *Ann Intern Med* 1988;108:387–389
- Lloyd AR, Wakefield D, Boughton C, et al. What is myalgic encephalomyelitis? *Lancet* 1988;1:1286–1287
- Lloyd AR, Hickie I, Boughton CR, et al. Prevalence of chronic fatigue syndrome in an Australian population. *Med J Aust* 1990;153:522–528
- Sharpe MC, Archard LC, Banatvala JE, et al. A report: chronic fatigue syndrome: guidelines for research. *J R Soc Med* 1991;84:118–121
- Maquet D, Demoulin C, Crielaard JM. Chronic fatigue syndrome: a systematic review. *Ann Readapt Med Phys* 2006;49(6):337–347, 418–427
- Lee S, Yu H, Wing Y, et al. Psychiatric morbidity and illness experience of primary care patients with chronic fatigue in Hong Kong. *Am J Psychiatry* 2000;157:380–384
- Davis MP, Khoshknabi D, Yue GH. Management of fatigue in cancer patients. *Curr Pain Headache Rep* 2006;10(4):260–269
- Pearce JM. The enigma of chronic fatigue. *Eur Neurol* 2006;56(1):31–36
- Pichot P. Neurasthenia, yesterday and today [in French]. *Encephale* 1994;20 Spec No 3:545–549
- Rangel L, Garralda ME, Jeffs J, et al. Family health and characteristics in chronic fatigue syndrome, juvenile rheumatoid arthritis, and emotional disorders of childhood. *J Am Acad Child Adolesc Psychiatry* 2005;44(2):150–158
- Endicott NA. Chronic fatigue syndrome in private practice psychiatry: family history of physical and mental health. *J Psychosom Res* 1999;47(4):343–354
- Buchwald D, Herrell R, Ashton S, et al. A twin study of chronic fatigue. *Psychosom Med* 2001;63(6):936–943
- Hickie I, Kirk K, Martin N. Unique genetic and environmental determinants of prolonged fatigue: a twin study. *Psychol Med* 1999;29(2):259–268
- Cho HJ, Skowera A, Cleare A, et al. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. *Curr Opin Psychiatry* 2006;19(1):67–73
- Klimas NG, Salvato FR, Morgan R, et al. Immunologic abnormalities in the chronic fatigue syndrome. *J Clin Microbiol* 1990;28:1403–1410
- Landay AL, Jessop C, Lennette ET, et al. Chronic fatigue syndrome: a clinical condition associated with immune activation. *Lancet* 1991;338:707–712
- Robertson MJ, Schacterle RS, Mackin GA, et al. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. *Clin Exp Immunol* 2005;141(2):326–332
- Lloyd A, Hickie I, Brockman A, et al. Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects. *J Infect Dis* 1991;164:1023–1024
- Staines DR. Postulated vasoactive neuropeptide autoimmunity in fatigue-related conditions: a brief review and hypothesis. *Clin Dev Immunol* 2006;13(1):25–39
- Byrne E. The chronic fatigue syndrome: a reappraisal and unifying hypothesis. *Clin Exp Neurol* 1991;28:128–138
- Nakaya T, Kuratsune H, Kitani T, et al. Demonstration on Borna disease virus in patients with chronic fatigue syndrome [in Japanese]. *Nippon Rinsho* 1997;55(11):3064–3071
- Li YJ, Wang DX, Bai XL, et al. Clinical characteristics of patients with chronic fatigue syndrome: analysis of 82 cases [in Chinese]. *Zhonghua Yi Xue Za Zhi* 2005;85(10):701–704
- Matano S, Kinoshita H, Tanigawa K, et al. Acute parvovirus B19 infection mimicking chronic fatigue syndrome. *Intern Med* 2003;42(9):903–905
- Kerr JR. Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. *J Vet Med B Infect Dis Vet Public Health* 2005;52(7–8):335–339
- White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *Br J Psychiatry* 1998;173:475–481
- Chia JK. The role of enterovirus in chronic fatigue syndrome. *J Clin Pathol* 2005;58(11):1126–1132
- Kondo K. Human herpesvirus latency and fatigue. *Uirusu* 2005;55(1):9–17
- Komaroff AL. Chronic fatigue syndromes: a preliminary overview. *Can Dis Wkly Rep* 1991;17:23–28
- Ablashi DV. Viral studies of chronic fatigue syndrome. *Clin Infect Dis* 1994;18(suppl 1):S130–S133
- White PD, Thomas JM, Sullivan PF, et al. The nosology of sub-acute and chronic fatigue syndromes that follow infectious mononucleosis. *Psychol Med* 2004;34(3):499–507
- Ng BY, Lim CC, Yeoh A, et al. Neuropsychiatric sequelae of Nipah virus encephalitis. *J Neuropsychiatry Clin Neurosci* 2004;16(4):500–504
- Parker NR, Barralet JH, Bell AM. Q fever. *Lancet* 2006;367(9511):679–688
- Masuda A, Nakayama T, Yamanaka T, et al. The prognosis after multidisciplinary treatment for patients with postinfectious chronic fatigue syndrome and noninfectious chronic fatigue syndrome. *J Behav Med* 2002;25(5):487–497
- Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. *Med Hypotheses* 2005;65(2):287–295
- Gotschalk M, Kumpfel T, Flachenecker P, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. *Arch Neurol* 2005 Feb;62(2):277–280
- Wessely S. The neuropsychiatry of chronic fatigue syndrome. *Ciba Found Symp* 1993;173:212–229; discussion 229–237
- Gaaf J, Engert V, Heitz V, et al. Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome. *J Psychosom Res* 2004;56(4):419–424
- Bakheit AM, Behan PO, Dinan TG, et al. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. *BMJ* 1992;304(6833):1010–1012
- Inder WJ, Prickett TC, Mulder RT. Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. *Clin Endocrinol (Oxf)* 2005;62(3):343–348
- Durlach J, Pages N, Bac P, et al. Chronopathological forms of magnesium depletion with hypofunction or with hyperfunction of the biological clock. *Magnes Res* 2002;15(3–4):263–268
- Kuratsune H, Yamaguti K, Sawada M, et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. *Int J Mol Med* 1998;1(1):143–146
- Nijs J, De Meirleir K. Impairments of the 2–5 synthetase/RNase L pathway in chronic fatigue syndrome. *In Vivo* 2005;19(6):1013–1021

46. Winkler AS, Blair D, Marsden JT, et al. Autonomic function and serum erythropoietin levels in chronic fatigue syndrome. *J Psychosom Res* 2004;56(2):179–183
47. Hatcher S, House A. Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. *Psychol Med* 2003; 33(7):1185–1192
48. Taylor RR, Jason LA. Chronic fatigue, abuse-related traumatization, and psychiatric disorders in a community-based sample. *Soc Sci Med* 2002;55(2):247–256
49. Heim C, Wagner D, Maloney E, et al. Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. *Arch Gen Psychiatry* 2006;63(11):1258–1266
50. Morriss R, Sharpe M, Sharpley AL, et al. Abnormalities of sleep in patients with the chronic fatigue syndrome. *BMJ* 1993;306(6886): 1161–1164
51. Morriss RK, Wearden AJ, Battersby L. The relation of sleep difficulties to fatigue, mood and disability in chronic fatigue syndrome. *J Psychosom Res* 1997;42(6):597–605
52. Friedlander AH, Mahler ME, Yagiela JA. Restless legs syndrome: manifestations, treatment and dental implications. *J Am Dent Assoc* 2006;137(6):755–761
53. Terman M, Levine SM, Terman JS, et al. Chronic fatigue syndrome and seasonal affective disorder: comorbidity, diagnostic overlap, and implications for treatment. *Am J Med* 1998;105(3A):1155–124S
54. Ghahramani M, Gooriah V. Chronic fatigue syndrome associated with a psychotic state resulting in multiple murders. *Bull Am Acad Psychiatry Law* 1995;23(4):613–616
55. Skapinakis P, Lewis G, Mavreas V. Unexplained fatigue syndromes in a multinational primary care sample: specificity of definition and prevalence and distinctiveness from depression and generalized anxiety. *Am J Psychiatry* 2003;160:785–787
56. Hawk C, Jason LA, Torres-Harding S. Differential diagnosis of chronic fatigue syndrome and major depressive disorder. *Int J Behav Med* 2006; 13(3):244–251
57. Moldofsky H. Nonrestorative sleep and symptoms after a febrile illness in patients with fibrositis and chronic fatigue syndromes. *J Rheumatol Suppl* 1989;19:150–153
58. Dendy C, Cooper M, Sharpe M. Interpretation of symptoms in chronic fatigue syndrome. *Behav Res Ther* 2001;39(11):1369–1380
59. Moss-Morris R, Petrie KJ. Discriminating between chronic fatigue syndrome and depression: a cognitive analysis. *Psychol Med* 2001; 31(3):469–479
60. White PD, Pinching AJ, Rakib A, et al. A comparison of patients with chronic fatigue syndrome attending separate clinics based in immunology and psychiatry. *J R Soc Med* 2002;95(9):440–444
61. David AS. Postviral fatigue syndrome and psychiatry. *Br Med Bull* 1991;47(4):966–988
62. Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. *J Neurol Neurosurg Psychiatry* 2000;69(3):302–307
63. Lawrie SM, MacHale SM, Cavanagh JT, et al. The difference in patterns of motor and cognitive function in chronic fatigue syndrome and severe depressive illness. *Psychol Med* 2000;30(2):433–442
64. Scott LV, Salahuddin F, Cooney J, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. *J Affect Disord* 1999;54(1–2):129–137
65. Sharpe M, Chalder T, Palmer I, et al. Chronic fatigue syndrome: a practical guide to assessment and management. *Gen Hosp Psychiatry* 1997;19(3):185–199
66. Glass JM. Cognitive dysfunction in fibromyalgia and chronic fatigue syndrome: new trends and future directions. *Curr Rheumatol Rep* 2006;8(6):425–429
67. Geisser ME, Gracely RH, Giesecke T, et al. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. *Eur J Pain* 2007;11(2):202–207
68. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. *Semin Arthritis Rheum* 2007;36(6):339–356
69. Brown MM, Jason LA. Functioning in individuals with chronic fatigue syndrome: increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. *Dyn Med* 2007;6:9
70. Cook DB, Nagelkirk PR, Poluri A, et al. The influence of aerobic fitness and fibromyalgia on cardiorespiratory and perceptual responses to exercise in patients with chronic fatigue syndrome. *Arthritis Rheum* 2006;54(10):3351–3362
71. Matsumoto Y. Fibromyalgia syndrome. *Nippon Rinsho* 1999;57(2): 364–369
72. Naschitz JE, Rosner I, Rozenbaum M, et al. The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. *QJM* 2003;96(2):133–142
73. Gallagher AM, Coldrick AR, Hedge B, et al. Is the chronic fatigue syndrome an exercise phobia? a case control study. *J Psychosom Res* 2005;58(4):367–373
74. Marshall GS, Gesser RM, Yamanishi K, et al. Chronic fatigue in children: clinical features, Epstein-Barr virus and human herpesvirus 6 serology and long term follow-up. *Pediatr Infect Dis J* 1991;10(4): 287–290
75. Buchwald D, Wener MH, Pearlman T, et al. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. *J Rheumatol* 1997;24(2):372–376
76. Swanink CM, Vercoulen JH, Bleijenberg G, et al. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. *J Intern Med* 1995;237(5):499–506
77. Natelson BH, Cohen JM, Brassloff I, et al. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. *J Neurol Sci* 1993;120(2):213–217
78. Cope H, Pernet A, Kendall B, et al. Cognitive functioning and magnetic resonance imaging in chronic fatigue. *Br J Psychiatry* 1995;167(1):86–94
79. Greco A, Tannock C, Brostoff J, et al. Brain MR in chronic fatigue syndrome. *AJNR Am J Neuroradiol* 1997;18(7):1265–1269
80. Lange G, DeLuca J, Maldjian JA, et al. Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. *J Neurol Sci* 1999; 171(1):3–7
81. Cook DB, Lange G, DeLuca J, et al. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. *Int J Neurosci* 2001;107(1–2):1–6
82. Lange G, Holodny AI, DeLuca J, et al. Quantitative assessment of cerebral ventricular volumes in chronic fatigue syndrome. *Appl Neuropsychol* 2001;8(1):23–30
83. de Lange FP, Kalkman JS, Bleijenberg G, et al. Gray matter volume reduction in the chronic fatigue syndrome. *Neuroimage* 2005;26(3): 777–781
84. Daugherty SA, Henry BE, Peterson DL, et al. Chronic fatigue syndrome in northern Nevada. *Rev Infect Dis* 1991;13(suppl 1):S39–S44
85. Caseras X, Mataix-Cols D, Giampietro V, et al. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. *Psychosom Med* 2006; 68(6):947–955
86. Tanaka M, Sadato N, Okada T, et al. Reduced responsiveness is an essential feature of chronic fatigue syndrome: a fMRI study. *BMC Neurol* 2006;6:9
87. Lange G, Steffener J, Cook DB, et al. Objective evidence of cognitive complaints in chronic fatigue syndrome: a BOLD fMRI study of verbal working memory. *Neuroimage* 2005;26(2):513–524
88. Okada T, Tanaka M, Kuratsune H, et al. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. *BMC Neurol* 2004;4(1):14
89. de Lange FP, Kalkman JS, Bleijenberg G, et al. Neural correlates of the chronic fatigue syndrome: an fMRI study [published online ahead of print July 7, 2004]. *Brain* 2004;127(pt 9):1948–1957. doi:10.1093/brain/ awh225
90. Goldstein J. Chronic Fatigue Syndrome: The Struggle for Health. Beverly Hills, Calif: Chronic Fatigue Syndrome Institute; 1990
91. Schwartz RB, Garada BM, Komaroff AL, et al. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. *AJR Am J Roentgenol* 1994;162(4):935–941
92. Siessmeier T, Nix WA, Hardt J, et al. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. *J Neurol Neurosurg Psychiatry* 2003;74(7):922–928
93. Yamamoto S, Ouchi Y, Onoe H, et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. *Neuroreport* 2004;15(17): 2571–2574
94. Puri BK. Proton and 31-phosphorus neurospectroscopy in the study of membrane phospholipids and fatty acid intervention in schizophrenia, depression, chronic fatigue syndrome (myalgic encephalomyelitis) and dyslexia. *Int Rev Psychiatry* 2006;18(2):145–147



95. Wang Q, Xiong JX. Clinical observation on electroacupuncture for treatment of chronic fatigue syndrome [in Chinese]. *Zhongguo Zhen Jiu* 2005;25(10):691–692
96. Price JR, Couper J. Cognitive behaviour therapy for adults with chronic fatigue syndrome. *Cochrane Database Syst Rev* 2000;2:CD001027
97. Akagi H, Klimes I, Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital: feasible and effective. *Gen Hosp Psychiatry* 2001;23(5):254–260
98. Deale A, Husain K, Chalder T, et al. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *Am J Psychiatry* 2001;158:2038–2042
99. Deale A, Chalder T, Marks I, et al. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. *Am J Psychiatry* 1997;154:408–414
100. Masuda A, Nakayama T, Yamanaka T, et al. Cognitive behavioral therapy and fasting therapy for a patient with chronic fatigue syndrome. *Intern Med* 2001;40(11):1158–1161
101. O'Dowd H, Gladwell P, Rogers CA, et al. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. *Health Technol Assess* 2006;10(37):iii–iv, ix–x, 1–121
102. Coutts R, Weatherby R, Davie A. The use of a symptom “self-report” inventory to evaluate the acceptability and efficacy of a walking program for patients suffering with chronic fatigue syndrome. *J Psychosom Res* 2001;51(2):425–429
103. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. *BMJ* 1997;314(7095):1647–1652
104. Friedberg F. Does graded activity increase activity? a case study of chronic fatigue syndrome. *J Behav Ther Exp Psychiatry* 2002;33(3–4):203–215
105. Powell P, Bentall RP, Nye FJ, et al. Patient education to encourage graded exercise in chronic fatigue syndrome: 2-year follow-up of randomised controlled trial. *Br J Psychiatry* 2004;184:142–146
106. Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. *J Clin Psychiatry* 1993;54:13–20
107. Natelson BH, Cheu J, Hill N, et al. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. *Neuropsychobiology* 1998;37(3):150–154
108. Klimas NG, Morgan R, Van Rid F, et al. Observations regarding use of an antidepressant, fluoxetine, in chronic fatigue syndrome. In: Goodnick PJ, Klimas NG, eds. *Chronic Fatigue and Related Immune Deficiency Syndromes*. Washington, DC: American Psychiatric Press; 1993:95–108
109. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. *Lancet* 1996;347(9005):858–861
110. Wearden AJ, Morriss RK, Mullis R, et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. *Br J Psychiatry* 1998;172:485–490
111. Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. *Biol Psychiatry* 1992;32:834–838
112. Schonfeldt-Lecuona C, Connemann BJ, Wolf RC, et al. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode [letter]. *Pharmacopsychiatry* 2006;39(4):152–154
113. Lecrubien Y. Antidepressant drugs: similar but different? In: Mendlewicz J, Brunello N, Langer SZ, et al, eds. *New Pharmacological Approaches to the Therapy of Depressive Disorders*. Basel, Switzerland: Karger; 1993:83–91
114. White PD, Cleary KJ. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. *Int Clin Psychopharmacol* 1997;12(1):47–52
115. Morriss RK, Robson MJ, Deakin JF. Neuropsychological performance and noradrenaline function in chronic fatigue syndrome under conditions of high arousal. *Psychopharmacology (Berl)* 2002;163(2):166–173
116. Cleare AJ, O'Keane V, Miell J. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion. *Clin Endocrinol (Oxf)* 2001;55(1):113–119
117. Puri BK, Holmes J, Hamilton G. Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. *Int J Clin Pract* 2004;58(3):297–299
118. Laviano A, Meguid MM, Guijarro A, et al. Antimyopathic effects of carnitine and nicotine. *Curr Opin Clin Nutr Metab Care* 2006;9(4):442–448
119. Randall DC, Cafferty FH, Shneerson JM, et al. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. *J Psychopharmacol* 2005;19(6):647–660
120. McDermott C, Richards SC, Thomas PW, et al. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. *QJM* 2006;99(7):461–468
121. Blockmans D, Persoons P, Van Houdenhove B, et al. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. *Am J Med* 2003;114(9):736–741
122. Williams G, Waterhouse J, Mugarza J, et al. Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. *Eur J Clin Invest* 2002;32(11):831–837